Overview

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Status:
Recruiting
Trial end date:
2025-05-29
Target enrollment:
Participant gender:
Summary
This phase II trial tests the safety, side effects and best dose of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that are growing, spreading, or getting worse (progressive), has come back (relapsed), or does respond to treatment (refractory). Tovorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and blocks over-active growth pathways in cancer cells. Giving tovorafenib may cause the tumor to stop growing or to shrink for a period of time.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)